2025-10-31 21:28:46
Latest Post
NTPC Green Energy Ltd Signs MoU with CtrlS Datacenter Limited for development of RE Projects
Lemon Tree Hotels signs 11th property in Punjab
DMRC signs MoU with Mappls MapmyIndia
R R Kabel Limited declares interim dividend of Rs. 4
Balkrishna Industries Ltd declares 2nd interim dividend of Rs. 4Stock Report
Strides Pharma Science Ltd consolidated Q2FY26 net profit climbs to Rs. 127.53 crores
Posted On : 2025-10-31 14:52:42( TIMEZONE : IST )
Strides Pharma Science Limited has reported Consolidated financial results for the period ended September 30, 2025.
Financial Results (Q2 FY2026) - QoQ Comparison
The company has reported total income of Rs. 1247.971 crores during the period ended September 30, 2025 as compared to Rs. 1128.319 crores during the period ended June 30, 2025.
The company has posted net profit / (loss) of Rs. 127.534 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs. 99.608 crores for the period ended June 30, 2025.
The company has reported EPS of Rs. 13.84 for the period ended September 30, 2025 as compared to Rs. 10.81 for the period ended June 30, 2025.
| Financials | Q2 FY2026 | Q1 FY2026 | % Change |
| Total Income | ₹ 1247.971 crs | ₹1128.319 crs |  10.60% |
| Net Profit | ₹127.534 crs | ₹99.608 crs | 28.04% |
| EPS | ₹13.84 | ₹10.81 | 28.03% |
Financial Results (Q2 FY2026) - YoY Comparison
The company has reported total income of Rs. 1247.971 crores during the period ended September 30, 2025 as compared to Rs.1195.345 crores during the period ended September 30, 2024.
The company has posted net profit / (loss) of Rs.127.534 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs.71.843 crores for the period ended September 30, 2024.
The company has reported EPS of Rs.13.84 for the period ended September 30, 2025 as compared to Rs.7.80 for the period ended September 30, 2024.
| Financials | Q2 FY2026 | Q2 FY2025 | % Change |
| Total Income | ₹ 1247.971 crs | ₹1195.345 crs | 4.40% |
| Net Profit | ₹127.534 crs | ₹71.843 crs | 77.52% |
| EPS | ₹13.84 | ₹7.80 | 77.44% |
Financial Results (Half Year Ended FY2026) - YoY Comparison
The company has reported total income of Rs.2376.290 crores during the 6 Months period ended September 30, 2025 as compared to Rs.2262.402 crores during the 6 Months period ended September 30, 2024.
The company has posted net profit / (loss) of Rs.227.142 crores for the 6 Months period ended September 30, 2025 as against net profit / (loss) of Rs.3423.315 crores for the 6 Months period ended September 30, 2024.
The company has reported EPS of Rs.24.64 for the 6 Months period ended September 30, 2025 as compared to Rs.371.75 for the 6 Months period ended September 30, 2024.
| Financials | Half Year Ended FY2026 | Half Year Ended FY2025 | % Change |
| Total Income | ₹2376.290 crs | ₹2262.402 crs | 5.03% |
| Net Profit | ₹227.142 crs | ₹3423.315 crs |  -93.36% |
| EPS | ₹24.64 | ₹371.75 | -93.37% |
Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 849.95 as compared to the previous close of Rs. 850.00. The total number of shares traded during the day was 6695 in over 651 trades.
The stock hit an intraday high of Rs. 863.00 and intraday low of 844.85. The net turnover during the day was Rs. 5707078.00.
